IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women

Stacey E.P. Joosten, Marius Wellenstein, Rutger Koornstra, Annelot van Rossum, Joyce Sanders, Vincent van der Noort, Maria C. Ferrandez, Rolf Harkes, Ingrid A.M. Mandjes, Hilde Rosing, Alwin Huitema, Jos H. Beijnen, Jelle Wesseling, Paul J. van Diest, Hugo M. Horlings, Sabine C. Linn, Wilbert Zwart

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

Samenvatting

Window studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tumor cell positivity for the proliferation marker Ki67 is often used as a proxy for treatment response. Immunohistochemistry (IHC)-based Ki67 on tissue from neo-adjuvant trials was previously reported to be predictive for long-term response to endocrine therapy for breast cancer in postmenopausal women, but none of these trials enrolled premenopausal women. Nonetheless, the marker is being used on this subpopulation. We compared pathologist assessed IHC-based Ki67 in samples from pre- and postmenopausal women in a neo-adjuvant, endocrine therapy focused trial (NCT00738777), randomized between tamoxifen, anastrozole, or fulvestrant. These results were compared with (1) IHC-based Ki67 scoring by AI, (2) mitotic figures, (3) mRNA-based Ki67, (4) five independent gene expression signatures capturing proliferation, and (5) blood levels for tamoxifen and its metabolites as well as estradiol. Upon tamoxifen, IHC-based Ki67 levels were decreased in both pre- and postmenopausal breast cancer patients, which was confirmed using mRNA-based cell proliferation markers. The magnitude of decrease of Ki67 IHC was smaller in pre- versus postmenopausal women. We found a direct relationship between post-treatment estradiol levels and the magnitude of the Ki67 decrease in tumors. These data suggest IHC-based Ki67 may be an appropriate biomarker for tamoxifen response in premenopausal breast cancer patients, but anti-proliferative effect size depends on estradiol levels.

Originele taal-2Engels
Artikelnummer138
Tijdschriftnpj Breast Cancer
Volume7
Nummer van het tijdschrift1
DOI's
StatusGepubliceerd - dec. 2021
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women'. Samen vormen ze een unieke vingerafdruk.

Citeer dit